CD28 antag 
Welcome,         Profile    Billing    Logout  
 2 Companies  1 Product   1 Product   0 Diseases   0 Trials   12 News 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
pegrizeprument (FR104) / OSE Immunotherapeutics, Asahi Kasei
2020-000599-38: Phase 1/2 study of FR104 first administration In patient with Renal Transplantation: FIRsT study Étude de phase 1/2 : première administration de FR104 chez des patients ayant une première transplantation rénale : étude FIRsT

Not yet recruiting
1/2
10
Europe
FR104, FR104, Solution for infusion
NANTES CHU, OSE Immunotherapeutics
Kidney transplant Transplantés rénaux, Kidney transplant Transplantés rénaux, Diseases [C] - Symptoms and general pathology [C23]
 
 
FIRsT Study, NCT04837092: Phase I/II Study of FR104 First Administration in Patient with Renal Transplantation:

Active, not recruiting
1/2
10
Europe
FR104
Nantes University Hospital, OSE Immunotherapeutics
Kidney Transplantation
03/25
03/25
NCT05238493: A Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VEL-101

Completed
1
60
US
VEL-101, Placebo
Veloxis Pharmaceuticals
Healthy Volunteers
01/23
01/23
acazicolcept (ALPN-101) / AbbVie
NCT04835441 / 2020-004047-86: ALPN-101 (Acazicolcept) in Systemic Lupus Erythematosus

Completed
2
76
Europe, US, RoW
ALPN-101, Placebo
Alpine Immune Sciences, Inc.
Systemic Lupus Erythematosus
07/24
07/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
pegrizeprument (FR104) / OSE Immunotherapeutics, Asahi Kasei
2020-000599-38: Phase 1/2 study of FR104 first administration In patient with Renal Transplantation: FIRsT study Étude de phase 1/2 : première administration de FR104 chez des patients ayant une première transplantation rénale : étude FIRsT

Not yet recruiting
1/2
10
Europe
FR104, FR104, Solution for infusion
NANTES CHU, OSE Immunotherapeutics
Kidney transplant Transplantés rénaux, Kidney transplant Transplantés rénaux, Diseases [C] - Symptoms and general pathology [C23]
 
 
FIRsT Study, NCT04837092: Phase I/II Study of FR104 First Administration in Patient with Renal Transplantation:

Active, not recruiting
1/2
10
Europe
FR104
Nantes University Hospital, OSE Immunotherapeutics
Kidney Transplantation
03/25
03/25
NCT05238493: A Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VEL-101

Completed
1
60
US
VEL-101, Placebo
Veloxis Pharmaceuticals
Healthy Volunteers
01/23
01/23
acazicolcept (ALPN-101) / AbbVie
NCT04835441 / 2020-004047-86: ALPN-101 (Acazicolcept) in Systemic Lupus Erythematosus

Completed
2
76
Europe, US, RoW
ALPN-101, Placebo
Alpine Immune Sciences, Inc.
Systemic Lupus Erythematosus
07/24
07/24

Download Options